📊 IMNM Key Takeaways
Is Immunome Inc. (IMNM) a Good Investment?
Immunome is a pre-commercial stage biotech company with minimal revenue of $6.9M that declined 40.8% year-over-year, posting operating losses of -$224.1M and burning $200.6M in annual free cash flow. While the company maintains a substantial cash position of $653.5M and virtually no debt, the accelerating revenue decline combined with massive operating losses and negative cash generation indicates fundamental commercial viability challenges that cannot be offset by balance sheet strength.
Immunome’s balance sheet is very strong, with ~$653M in cash, minimal debt, and a ~14.7x current ratio that supports a multi‑year runway. However, fundamentals are weak: revenue is small and declining, margins are deeply negative, and free cash flow is heavily negative, indicating no near‑term path to profitability. On fundamentals alone, the robust liquidity offsets solvency risk but not the execution and commercialization risks.
Why Buy Immunome Inc. Stock? IMNM Key Strengths
- Strong cash position of $653.5M provides multi-year operational runway
- Minimal debt (0.00x debt-to-equity) with only $500K long-term debt
- Exceptional liquidity with 14.69x current ratio
- Exceptional liquidity and cash runway (~$653M cash)
- Minimal leverage and strong equity base
- Large asset base relative to low liabilities
IMNM Stock Risks: Immunome Inc. Investment Risks
- Revenue declining sharply at -40.8% YoY with only $6.9M in sales
- Operating cash burn of $190.9M annually with no path to profitability visible
- Operating losses of $224.1M are 32x greater than revenue, indicating business is not yet viable
- Negative free cash flow of -$200.6M will deplete cash reserves within 3+ years if burn continues
- Sustained high cash burn and deeply negative FCF
- Declining revenue with no clear gross margin/commercial traction
- Potential future dilution/financing needs once runway shortens
Key Metrics to Watch
- Revenue trajectory and stabilization of top-line growth
- Quarterly cash burn rate and remaining cash runway
- Pipeline progress and clinical trial advancement toward commercialization
- Path to positive operating cash flow and gross margin expansion
- Operating cash flow (quarterly burn rate)
- R&D + G&A expense trend
Immunome Inc. (IMNM) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 14.69x current ratio provides a solid financial cushion.
IMNM Profit Margin, ROE & Profitability Analysis
IMNM vs Healthcare Sector: How Immunome Inc. Compares
How Immunome Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Immunome Inc. Stock Overvalued? IMNM Valuation Analysis 2026
Based on fundamental analysis, Immunome Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Immunome Inc. Balance Sheet: IMNM Debt, Cash & Liquidity
IMNM Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Immunome Inc.'s revenue has declined by 36% over the 5-year period, indicating business contraction. The most recent EPS of $-5.00 indicates the company is currently unprofitable.
IMNM Revenue Growth, EPS Growth & YoY Performance
IMNM Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | N/A | -$36.1M | $-0.65 |
| Q2 2025 | $2.4M | -$36.1M | $-0.50 |
| Q1 2025 | $1.0M | -$41.6M | $-0.52 |
| Q3 2024 | $2.9M | -$4.3M | $-0.36 |
| Q2 2024 | $2.4M | -$4.3M | $-0.46 |
| Q1 2024 | $1.0M | -$4.3M | $-0.35 |
| Q3 2023 | $3.6M | -$4.3M | $-0.36 |
| Q2 2023 | $4.3M | -$5.6M | $-0.46 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Immunome Inc. Dividends, Buybacks & Capital Allocation
IMNM SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Immunome Inc. (CIK: 0001472012)
📋 Recent SEC Filings
| Date | Form | Document | Action |
|---|---|---|---|
| Apr 3, 2026 | 4 | xslF345X06/form4-04032026_110409.xml | View → |
| Apr 3, 2026 | 4 | xslF345X06/form4-04032026_110446.xml | View → |
| Apr 1, 2026 | 4 | xslF345X06/form4-04012026_090411.xml | View → |
| Mar 31, 2026 | 4 | xslF345X06/form4-03312026_110335.xml | View → |
| Mar 23, 2026 | 4 | xslF345X06/form4-03242026_010325.xml | View → |
❓ Frequently Asked Questions about IMNM
What is the AI rating for IMNM?
Immunome Inc. (IMNM) has a Combined AI Rating of SELL from Claude (STRONG SELL) and ChatGPT (HOLD) with 76% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are IMNM's key strengths?
Claude: Strong cash position of $653.5M provides multi-year operational runway. Minimal debt (0.00x debt-to-equity) with only $500K long-term debt. ChatGPT: Exceptional liquidity and cash runway (~$653M cash). Minimal leverage and strong equity base.
What are the risks of investing in IMNM?
Claude: Revenue declining sharply at -40.8% YoY with only $6.9M in sales. Operating cash burn of $190.9M annually with no path to profitability visible. ChatGPT: Sustained high cash burn and deeply negative FCF. Declining revenue with no clear gross margin/commercial traction.
What is IMNM's revenue and growth?
Immunome Inc. reported revenue of $6.9M.
Does IMNM pay dividends?
Immunome Inc. does not currently pay dividends.
Where can I find IMNM SEC filings?
Official SEC filings for Immunome Inc. (CIK: 0001472012) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is IMNM's EPS?
Immunome Inc. has a diluted EPS of $-2.43.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is IMNM a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Immunome Inc. has a SELL rating with 76% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is IMNM stock overvalued or undervalued?
Valuation metrics for IMNM: ROE of -33.5% (sector avg: 15%), net margin of -3,060.0% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy IMNM stock in 2026?
Our dual AI analysis gives Immunome Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is IMNM's free cash flow?
Immunome Inc.'s operating cash flow is $-190.9M, with capital expenditures of $9.7M. FCF margin is -2,890.1%.
How does IMNM compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -3,060.0% (avg: 12%), ROE -33.5% (avg: 15%), current ratio 14.69 (avg: 2).